SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-094875
Filing Date
2024-04-12
Accepted
2024-04-12 17:12:05
Documents
21
Period of Report
2024-04-11
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d818273d8k.htm   iXBRL 8-K 32414
2 EX-1.1 d818273dex11.htm EX-1.1 287053
3 EX-4.1 d818273dex41.htm EX-4.1 61208
4 EX-5.1 d818273dex51.htm EX-5.1 18915
5 EX-99.1 d818273dex991.htm EX-99.1 9720
9 GRAPHIC g818273g0412071557368.jpg GRAPHIC 2053
10 GRAPHIC g818273page1a.jpg GRAPHIC 10184
11 GRAPHIC g818273page1c.jpg GRAPHIC 8856
12 GRAPHIC g818273page2b.jpg GRAPHIC 9465
  Complete submission text file 0001193125-24-094875.txt   666878

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA nrix-20240411.xsd EX-101.SCH 2850
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE nrix-20240411_lab.xml EX-101.LAB 17994
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nrix-20240411_pre.xml EX-101.PRE 11261
24 EXTRACTED XBRL INSTANCE DOCUMENT d818273d8k_htm.xml XML 3642
Mailing Address 1700 OWENS STREET, SUITE 205 SAN FRANCISCO CA 94158
Business Address 1700 OWENS STREET, SUITE 205 SAN FRANCISCO CA 94158 (415) 660-5320
Nurix Therapeutics, Inc. (Filer) CIK: 0001549595 (see all company filings)

IRS No.: 270838048 | State of Incorp.: DE | Fiscal Year End: 1130
Type: 8-K | Act: 34 | File No.: 001-39398 | Film No.: 24842319
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)